Ventola Cl

1.5k total citations · 1 hit paper
11 papers, 1.1k citations indexed

About

Ventola Cl is a scholar working on Immunology, Pharmacology and Economics and Econometrics. According to data from OpenAlex, Ventola Cl has authored 11 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Immunology, 3 papers in Pharmacology and 3 papers in Economics and Econometrics. Recurrent topics in Ventola Cl's work include Pharmaceutical industry and healthcare (3 papers), Health Systems, Economic Evaluations, Quality of Life (2 papers) and Biosimilars and Bioanalytical Methods (2 papers). Ventola Cl is often cited by papers focused on Pharmaceutical industry and healthcare (3 papers), Health Systems, Economic Evaluations, Quality of Life (2 papers) and Biosimilars and Bioanalytical Methods (2 papers). Ventola Cl collaborates with scholars based in United States. Ventola Cl's co-authors include and has published in prestigious journals such as PubMed.

In The Last Decade

Ventola Cl

10 papers receiving 1.1k citations

Hit Papers

Progress in Nanomedicine: Approved and Investigational Na... 2017 2026 2020 2023 2017 100 200 300 400 500

Peers

Ventola Cl
Comparison fields: 5 of 131
  • Biomaterials 316
  • Molecular Biology 308
  • Biomedical Engineering 300
  • Oncology 214
  • Immunology 214
Replace Nan Zheng with:
Nan Zheng China
James L. Weaver United States
Pravin Chaturvedi United States
Abid Hussain China
Joon Seok Bang South Korea
Connie Cheng United States
Kaili Wang China
Wei Hong China
Paola Brusa Italy
Zehui He China
Nan Zheng China View profile →
Citations per field, relative to Ventola Cl
Ventola Cl · 1×
Citations per year, relative to Ventola Cl
Ventola Cl · 1×

Countries citing papers authored by Ventola Cl

Since Specialization
Citations

This map shows the geographic impact of Ventola Cl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ventola Cl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ventola Cl more than expected).

Fields of papers citing papers by Ventola Cl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ventola Cl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ventola Cl. The network helps show where Ventola Cl may publish in the future.

No nodes

All Works

11 of 11 papers shown
# Work Indexed citations
1
Big Data and Pharmacovigilance: Data Mining for Adverse Drug Events and Interactions.
53
2
Progress in Nanomedicine: Approved and Investigational Nanodrugs. breakdown →
598
3
Cancer Immunotherapy, Part 3: Challenges and Future Trends.
188
4
Cancer Immunotherapy, Part 1: Current Strategies and Agents.
89
5
Evaluation of Biosimilars for Formulary Inclusion: Factors for Consideration by P&T Committees.
15
6
Epilepsy management: newer agents, unmet needs, and future treatment strategies.
30
7
The role of pharmacogenomic biomarkers in predicting and improving drug response: part 2: challenges impeding clinical implementation.
12
8
Direct-to-Consumer Pharmaceutical Advertising: Therapeutic or Toxic?
120
9
Current Issues Regarding Complementary and Alternative Medicine (CAM) in the United States: Part 2: Regulatory and Safety Concerns and Proposed Governmental Policy Changes with Respect to Dietary Supplements.
30
10
President Obama's health care reform policies: Issues of interest to P&T committees.
1
11
An Interview Series with Members of the ASHP Expert Panel on Formulary Management: Part 2: J. Russell May, PharmD.
1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026